Klinger, Christoph; Riecken, Bettina; Schmidt, Arthur; De Gottardi, Andrea; Meier, Benjamin; Bosch, Jaime; Caca, Karel (2017). Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Digestive and liver disease, 49(12), pp. 1345-1352. Elsevier 10.1016/j.dld.2017.05.020
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S1590865817308976-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) | Request a copy |
BACKGROUND & AIMS
Therapeutic anticoagulation is the standard treatment in patients with acute non-cirrhotic portal vein thrombosis (PVT). In critically ill patients, anticoagulation only may not suffice to achive rapid and stable recanalization. This study evaluates efficacy and safety of transjugular interventional therapy in acute non-cirrhotic PVT.
METHODS
This retrospective study includes 17 consecutive patients with acute noncirrhotic, non-malignant PVT. Main indication for interventional therapy was imminent intestinal infarction (n=10). Treatment consisted of a combination of transjugular thrombectomy, local fibrinolysis and - depending on thrombus resolution - transjugular intrahepatic portosystemic shunt.
RESULTS
Recanalization was successful in 94.1%. One- and two-year secondary PV patency rates were 88.2%. Major complications (n=3) resolved spontaneously in all but one patient (heparin induced thrombocytopenia type 2 with intestinal infarction). Symptoms improved in all patients. However, segmental bowel resection had to be performed in two (11.8%). During a median follow-up of 28.6 months, no patient experienced portal hypertensive complications. Presence of JAK2 V617F mutation predicted both short-term and long-term technical success.
CONCLUSIONS
Transjugular recanalization is safe and effective in patients with acute non-cirrhotic, non-malignant PVT. It should be considered especially in patients with imminent bowel infarction and low likelihood of recanalization following therapeutic anticoagulation. Patients with JAK2 mutation ought to be followed meticulously.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Hepatology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Hepatologie |
UniBE Contributor: |
De Gottardi, Andrea, Bosch, Jaime |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1590-8658 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Thi Thao Anh Pham |
Date Deposited: |
20 Feb 2018 15:47 |
Last Modified: |
02 Mar 2023 23:30 |
Publisher DOI: |
10.1016/j.dld.2017.05.020 |
PubMed ID: |
28733177 |
Uncontrolled Keywords: |
JAK2 mutation Local thrombolysis Portal vein thrombosis Transjugular intrahepatic portosystemic shunt |
BORIS DOI: |
10.7892/boris.109567 |
URI: |
https://boris.unibe.ch/id/eprint/109567 |
Actions (login required)
 |
Edit item |